

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

Guy de Bruyn MD,^{*1} Joyce Wang MS,² Annie Purvis MSPH,³ Martin Sanchez Ruiz MD,⁴ Haritha Adhikarla PhD,¹ Saad Alvi MD,⁵ Matthew I Bonaparte PhD,¹ Daniel Brune MD,⁶ Agustin Bueso MD,⁷ Richard M Canter MS,¹ Maria Angeles Ceregido PhD,⁸ Sachin Deshmukh MD,⁹ David Diemert MD,¹⁰ Adam Finn MD,¹¹ Remi Forrat MD,¹² Bo Fu PhD,¹ Julie Gallais MS,¹² Paul Griffin MBBS,¹³ Marie-Helene Grillet MD,¹⁴ Owen Haney PharmD,¹ Jeffrey A Henderson MD,¹⁵ Marguerite Koutsoukos MS,⁸ Odile Launay MD,¹⁶ Federico Martinon Torres MD¹⁷ Roger Masotti MS,¹ Nelson L Michael MD,¹⁸ Juliana Park MD,¹⁹ Doris M Rivera M MD,²⁰ Natalya Romanyak PharmD,¹ Chris Rook MB,²¹ Lode Schuerman MD,⁸ Lawrence D Sher MD,²² Fernanda Tavares-Da-Silva MD,^{8†} Ashley Whittington MD,²³ Roman M Chicz PhD,³ Sanjay Gurunathan MD,¹ Stephen Savarino MD,^{1†} Saranya Sridhar DPhil²⁴ on behalf of the VAT00002 booster cohorts study team.[‡]

1. Sanofi, Swiftwater, PA, USA
2. Sanofi, Chengdu, China
3. Sanofi, Cambridge, MA, USA
4. Sanofi, Paris, France
5. Chicago Clinical Research Institute, IL, USA
6. Optimal Research, Peoria, IL, USA
7. Demedica, San Pedro Sula, Honduras
8. GSK, Wavre, Belgium
9. Griffith University, Australia
10. School of Medicine and Health Sciences, George Washington University, Washington, DC, USA
11. Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
12. Sanofi, Marcy l'Etoile, France
13. Mater Health, Brisbane, Queensland, Australia. The University of Queensland, Brisbane, Queensland, Australia
14. Sanofi, Lyon, France
15. Black Hills Center for American Indian Health, SD, USA
16. Université Paris Cité; Inserm, F-CRIN I REIVAC, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
17. Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain; Genetics- Vaccines- Infectious Diseases and Pediatrics research group GENVIP, Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

18. Walter Reed Army Institute of Research, Silver Spring, MD, USA
19. Sanofi, Sydney, Australia
20. INVERIME S.A, Tegucigalpa, Honduras
21. Cmax, Adelaide, Australia
22. Peninsula Research Associates, Rolling Hills Estates, CA, USA
23. London North West University Healthcare NHS Trust, London, UK
24. Sanofi, Reading, UK

***Corresponding Author:** Guy de Bruyn, Sanofi, Swiftwater, PA, USA, Guy.DeBruyn@sanofi.com; Tel:

+15709725671

†Affiliation at time of study conduct.

‡VAT00002 booster cohorts study team members are listed in the Supplementary Appendix

1 **Abstract**

2 *Background*

3 Booster vaccines providing protection against emergent SARS-CoV-2 variants are needed. In an
4 international phase 3 study, we evaluated booster vaccines containing prototype (D614) and/or Beta
5 (B.1.351) variant recombinant spike proteins and AS03 adjuvant (CoV2 preS dTM-AS03).

6 *Methods*

7 Adults, primed 4–10 months earlier with mRNA (BNT162b2, mRNA-1273)), adenovirus-vectored
8 (Ad26.CoV2.S, ChAdOx1nCoV-19) or adjuvanted protein (CoV2 preS dTM-AS03 [D614]) vaccines and
9 stratified by age (18-55 and ≥56 years), were boosted with monovalent (MV) D614 (5µg, n=1285),
10 MV (B.1351) (5µg, n=707) or bivalent (BiV) (2.5µg D614 plus 2.5µg B.1.351, n=625) CoV2 preS dTM-
11 AS03. SARS-CoV-2-naïve adults (controls, n=479) received a primary series (two injections, 21 days
12 apart) of CoV2 preS dTM-AS03 containing 10µg D614. Antibodies to D614G, B.1.351 and Omicron
13 BA.2 and BA.1 variants were evaluated using validated pseudovirus (lentivirus) neutralization (PsVN)
14 assay. D614G or B.1.351 PsVN titers 14 days (D15) post-booster were compared with pre-booster
15 (D1) titers in BNT162b2-primed participants (18-55 years old) and controls (D36), for each booster
16 formulation (co-primary objectives). Safety was evaluated throughout the trial. Results of a planned
17 interim analysis are presented.

18 *Results*

19 Among BNT162b2-primed adults (18-55 years old), PsVN titers against D614G or B.1.351 were
20 significantly higher post-booster than anti-D614G titers post-primary vaccination in controls, for all
21 booster formulations, with an anti-D614G GMT ratio (98.3% CI) of 2.16 (1.69; 2.75) for MV(D614), an
22 anti-B.1.351 ratio of 1.96 (1.54; 2.50) for MV (B.1.351) and anti-D614G and anti-B.1.351 ratios of
23 2.34 (1.84; 2.96) and 1.39 (1.09; 1.77), respectively, for BiV. All booster formulations elicited cross-
24 neutralizing antibodies against Omicron BA.2 across vaccine priming subgroups and against Omicron

25 BA.1 (evaluated in BNT162b2-primed participants). Similar patterns in antibody responses were
26 observed for participants aged ≥ 56 years. No safety concerns were identified.

27 *Conclusion*

28 CoV2 preS dTM-AS03 boosters demonstrated acceptable safety and elicited robust neutralizing
29 antibodies against multiple variants, regardless of priming vaccine.

30 **ClinicalTrials.gov:** NCT04762680

31 **Funding:** Sanofi and federal funds from the Biomedical Advanced Research and Development
32 Authority (BARDA), part of the office of the Administration for Strategic Preparedness and Response
33 at the U.S. Department of Health and Human Services under Contract # HHSO100201600005I, and in
34 collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical,
35 Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.

36 **Keywords:** SARS-CoV-2, COVID-19, recombinant protein vaccine, AS03 adjuvant, booster,
37 immunogenicity, safety, Beta, B.1.351, Omicron

38 Introduction

39 The COVID-19 pandemic has seen an unprecedented deployment of COVID-19 vaccines.¹⁻³ The
40 continued emergence of new variants of concern (VoC) of the severe acute respiratory syndrome
41 coronavirus 2 (SARS-CoV-2), together with waning immunity and protection against mild and
42 moderately symptomatic infection, underscore the need for new and updated booster vaccines to
43 enhance and broaden protection.⁴⁻⁹ Bivalent boosters, targeting the prototype virus and Omicron
44 BA.1 or BA.4 and BA.5 subvariants have recently been authorized for use in the EU, USA and the
45 UK.¹⁰⁻¹³ While Omicron variant-containing vaccines were designed to include the predominant
46 circulating strain, an alternative approach is to include strains that provide broad cross-protection
47 against emergent variants.¹⁴

48 Sanofi and GSK have developed a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant
49 (CoV2 preS dTM-AS03) using a baculovirus vector system to express stabilized SARS-CoV-2 pre-fusion
50 S protein (preS dTM).¹⁵ In parallel with development of a D614 strain containing booster and primary
51 series vaccine¹⁶, we developed and are evaluating a CoV2 preS dTM-AS03 booster formulation
52 containing 5 µg of B.1.351 variant S protein (monovalent B.1.351) and a formulation containing 2.5
53 µg of D614 plus 2.5 µg of B.1.351 variants (bivalent D614+B.1.351). In previously primed non-human
54 primates, Beta (B.1.351) variant-containing adjuvanted recombinant protein vaccines showed broad
55 cross-reactivity across SARS-CoV-2 variants of concern and SARS-CoV-1.^{17,18}

56 Here, we present interim safety and immunogenicity data for three CoV2 preS dTM-AS03 booster
57 formulations (monovalent D614, monovalent B.1.351 and bivalent D614+B.1.351) in participants
58 from our phase 3 cohorts, who were previously primed with authorized COVID-19 mRNA or
59 adenovirus-vectored vaccines, or with CoV2 preS dTM-AS03 (5, 10 or 15 µg of D614 antigen).

60 **Methods**

61 *Study design and participants*

62 In a substantial amendment to the Phase 2 primary series study (NCT04762680)¹⁶ on June 10 2021,
63 two supplemental cohorts (cohort 1 and cohort 2) were added for phase 3 evaluation of the safety
64 and immunogenicity of monovalent D614, monovalent B.1.351 and bivalent D614+B.1.351 CoV2
65 preS dTM-AS03 booster formulations (**Figure S1**). Booster groups in both cohorts included adults
66 (≥ 18 years) from France, the USA, the UK, Australia and Spain who had completed a primary series of
67 an authorized or approved D614 mRNA vaccine (2 doses of BNT162b2 [30 μg ; Pfizer/BioNTech] or
68 mRNA-1273 [100 μg ; Moderna]) or adenovirus-vectored vaccine (2 doses of ChAdOx1 nCoV-19
69 [5×10^{10} vp; Oxford University/AstraZeneca] or 1 dose of Ad26.CoV2.S [5×10^{10} vp; J&J/Janssen]) at
70 least 4 months and no longer than 10 months prior to enrolment. Cohort 2 included a subgroup of
71 adults from the USA and Honduras who were previously primed in the original phase 2 study 4–10
72 months earlier with two doses of CoV2 preS dTM-AS03 containing 5, 10 or 15 μg of D614 antigen.
73 Cohort 1 included a parallel, non-randomized control group, encompassing unvaccinated adults, 18–
74 55 years of age, from the USA and Australia who tested negative for antibodies to SARS-CoV-2 with a
75 rapid diagnostic test (COVID-19 IgG and IgM Rapid Test Cassette; Healgen Scientific, Houston, TX,
76 USA). Individuals with pre-existing medical conditions, those who were immunocompromised
77 (except those with organ transplant in the past 180 days, chemotherapy in the past 90 days or with
78 HIV and CD4 counts $< 200/\text{mm}^3$) and those with a potentially increased risk for severe COVID-19¹⁹
79 were eligible for participation in the study. The exclusion criteria are described in full in the
80 **Supplementary Appendix, Methods**. Vaccine administration was open-label in cohort 1 booster and
81 control groups and modified double-blind (observer-blinded) in cohort 2.
82 Participants were enrolled between 29 July 2021 and 22 October 2021 to cohort 1 and between 15
83 November 2021 and 22 February 2022 to cohort 2. Here, we report interim immunogenicity data up
84 to 14 days after last vaccination in all participants and safety data up to cut-off dates 18 February

85 2022 for cohort 1 and 13 May 2022 for cohort 2. For controls, long-term safety analyses were
86 conducted up to 13 May 2022.

87 The study was undertaken in compliance with the International Conference on Harmonization
88 guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The protocol
89 and amendments were approved by Independent Ethics Committees (country ethics committees for
90 Honduras [Comité Ética Independiente Zugueme], France [Comite De Protection Des Personnes Ile
91 De France III Hôpital Tarnier-Cochin, France], Spain [Comité De Étidade Investigación Con
92 Medicamentos Parc Tauli, Spain] and the UK [HRA and Health and Care Research Wales, UK], a
93 central ethics committee for the USA [Advarra] and local ethics committees for the USA [WCG IRB,
94 Columbia Research Human Research Protection Office, Langone Health Office of Science and
95 Research Institutional Review Board and the Yale Human Research Protection Program] and for
96 Australia [Bellberry, Sydney Children’s Hospitals Network Human Research Ethics Committee and
97 Sydney Children's Hospital Network (SCHN) Research Governance]) as per local regulations. Written
98 informed consent was obtained from all participants before any study procedures were performed.

99 *Procedures*

100 Booster cohort participants were stratified by priming vaccine and by age category (18–55 years or
101 ≥ 56 years) (**Figure S1**). In the cohort 1 booster groups, all participants were offered a dose of
102 monovalent D614. In cohort 2, participants primed with an mRNA or adenovirus-vectored vaccine
103 were randomized 1:1 to receive monovalent B.1.351 or bivalent D614+B.1.351 boosters; while those
104 previously primed with CoV2 preS dTM-AS03 (5, 10 or 15 μg of D614 antigen) were randomized 9:1
105 (18–55-year-olds) or 1:1 (≥ 56 year-olds) to receive monovalent D614 or monovalent B.1.351
106 boosters, respectively. Participants in the control group received two injections, 21 days apart (D1
107 and D22), of CoV2 preS dTM-AS03 containing 10 μg of D614 antigen.

108 The CoV2 preS dTM-AS03 vaccine was described previously.^{15,16} Preparation of the booster
109 formulations and intramuscular administration are described in **Supplementary Methods**.

110 *Immunogenicity*

111 SARS-CoV-2 neutralizing antibody responses were measured using a lentivirus-based pseudovirus
112 neutralization (PsVN) assay expressing the full-length S protein of the SARS-CoV-2 D614G, Beta
113 (B.1.351) or Omicron (BA.1 or BA.2) variants (Monogram Biosciences LabCorp, South San Francisco,
114 CA, USA; **Supplementary Methods**).²⁰

115 Primary endpoints were individual serum PsVN titers at D1 and D15 against D614G for monovalent
116 D614 recipients, against B.1.351 for monovalent B.1.351 recipients, against D614G and B.1.351 for
117 bivalent D614+B.1.351 recipients, and against D614G 14 days after the last dose (D36) for the
118 control group. Secondary endpoints included PsVN titers against D614G and B.1.351 for each
119 predefined timepoint, the percentage of participants reaching a ≥ 4 -fold rise in serum neutralization
120 titer post-vaccination (D15 for booster cohorts; D22 and D36 for the control group) relative to pre-
121 vaccination (D1) and individual serum neutralization titer fold-rise. Exploratory endpoints included
122 individual serum PsVN titers against Omicron subvariants BA.2 and BA.1 in available samples across
123 all priming vaccine subgroups for BA.2 and from BNT162b2-primed participants for BA.1.

124 *Safety*

125 Safety was assessed for each treatment group and by age category (18–55 years or ≥ 56 years).
126 Safety endpoints were as described in the original phase 2 study,¹⁶ with the list of AEs of special
127 interest (AESIs) updated to include anaphylactic reactions, generalized convulsions,
128 thrombocytopenia, thrombosis with thrombocytopenia syndrome, myocarditis, pericarditis and
129 potential immune-mediated diseases (pIMDs).^{21,22} Adverse events (AEs) were graded from grade 1
130 (mild) to grade 3 (severe; prevents normal daily activities) and assessed by the investigator as
131 related or unrelated to the study vaccine.

132 *Statistics*

133 Co-primary immunogenicity objectives were to demonstrate, for BNT162b2-primed participants 18–
134 55 years of age: i) the non-inferiority of post-booster D614G PsVN responses following monovalent
135 D614, post-booster B.1.351 PsVN responses following monovalent B.1.351 or both responses
136 following bivalent D614+B.1.351, compared to the D614G PsVN response elicited by primary
137 vaccination in the control group; and ii) the superiority of the post-booster relative to pre-booster
138 PsVN response. Statistical inference was based on the use of two-sided 98.3% CIs. Non-inferiority in
139 terms of neutralizing antibody titers was concluded if the lower bound of the 98.3% CI for the
140 between-group (booster versus control) GMT ratio was >0.67 . Superiority in terms of neutralizing
141 antibody titers was concluded if the lower limit of the 2-sided 98.3% CI of the geometric mean of
142 individual ratio (GMTR; post-booster versus pre-booster) was >2 . Study objectives are described in
143 more detail in the **Supplementary Methods**.

144 The per-protocol analysis set (PPAS) comprised all participants who received the booster injection or
145 both primary vaccinations (control group), who met all protocol inclusion and no exclusion criteria,
146 provided blood samples on D15 (booster cohorts) or D22 and D36 (control group), did not have pre-
147 specified protocol deviations and did not receive a COVID-19 vaccine outside of this study before
148 D15 (booster cohorts) or D36 (control group). Analyses in the control group were performed on
149 SARS-CoV-2 naïve participants from the PPAS. Naïve or non-naïve status was determined based on
150 serological detection of anti-S antibodies on D1 (S-ELECSYS; Elecsys Anti-SARS-CoV-2 S, Roche,
151 Indianapolis, IN, USA EUA202698) and nucleic-acid amplification test (NAAT; Abbott RealTime SARS-
152 CoV-2 assay, EUA200023) for detection of SARS-CoV-2 in nasopharyngeal swabs on D1 and D22
153 (**Supplementary Methods**). The safety analysis set (SafAS) comprised all participants who received at
154 least one study vaccine dose, with analysis according to the vaccine actually received.

155 For full details on statistical considerations, including planned sample sizes, see **Supplementary**
156 **Methods**. Statistical analyses were performed using SAS® Version 9.4 or later.

157 Results

158 Participants and participant disposition

159 Allocated booster doses were administered to 803 of 806 participants enrolled into the monovalent
160 D614 group, 705 of 707 participants enrolled into the monovalent B.1.351 group and 621 of 625
161 enrolled into the bivalent D614+B.1.351 group. In the control group, 473 of 479 enrolled SARS-CoV-
162 2-naïve participants received at least one primary dose of monovalent D614. A total of 18
163 monovalent D614 booster recipients, 34 monovalent B.1.351 booster recipients, 26 bivalent
164 D614+B.1.351 recipients and 43 participants in the control group discontinued the study before the
165 analysis cut-off (**Figure S2**). The median interval between last primary and booster doses tended to
166 be slightly shorter overall for monovalent D614 recipients (5.75 months) than for monovalent
167 B.1.351 or bivalent D614+B.1.351 recipients (6.96 and 6.50 months, respectively) (**Table 1**). Across
168 the three booster groups (SafAS), the mean age (standard deviation [SD]) ranged from 43.7 (14.3) to
169 50.4 (15.0) years; 22.2%–37.5% were ≥56 years old. Control group participants had a mean age of
170 37.5 (11.2) years. The majority of participants (65.5%–78.7% across booster and control groups)
171 were white. Across booster and control groups, 50.8%–59.8% of participants had at least one high-
172 risk medical condition (**Table 1**), of which obesity was the most common (**Table S1**). Among booster
173 groups in the PPAS, prior SARS-CoV-2 infection based on anti-nucleoprotein seropositivity was
174 detected at baseline for 68/734 (9.3%) of monovalent D614 recipients, 138/615 (22.4%) of
175 monovalent B.1.351 recipients and 124/561 (22.1%) of bivalent vaccine recipients.

176 Immunogenicity

177 *Monovalent D614 booster*

178 Among participants aged 18–55 years, the D614G PsVN GMT for BNT162b2-primed participants
179 increased from 339 at D1 to 7894 (95% CI: 6993; 8911) on D15 following monovalent D614 booster,
180 demonstrating superiority of the PsVN response post-booster compared to pre-booster (post/pre-

181 booster ratio, 23.37 [98.3% CI: 18.58; 29.38]). PsVN titers against D614G at D15 were twice the level
182 of those induced after primary vaccination with CoV2 preS dTM-AS03 (D614) in the control group
183 (D36 GMT: 3658 [95% CI 3123; 4286]) demonstrating non-inferiority (GMT ratio of 2.16 [98.3% CI:
184 1.69; 2.75]) to the control group. Thus, the co-primary objectives for the monovalent D614 booster
185 group were met (**Table 2A**; see **Table S3** for PsVN titers in the control group).

186 Non-inferiority versus the control group was demonstrated for the pooled mRNA vaccine-primed
187 group (GMT ratio, 2.09 [98.3% CI: 1.66; 2.64]), the pooled adenovirus vectored vaccine-primed
188 group (GMT ratio, 1.89 [98.3% CI: 1.43; 2.49]) and the CoV2 preS dTM-AS03 (D614)-primed group
189 (GMT ratio, 7.27 [98.3% CI: 5.34; 9.89]). Superiority versus the pre-booster response was also
190 demonstrated for the mRNA-primed group (GMTR, 18.08 [98.3% CI: 14.75; 22.16]), for the
191 adenovirus-vectored primed group (GMTR, 30.18 [98.3% CI: 20.56; 44.31]) and the CoV2 preS dTM-
192 AS03 (D614) group (GMTR, 51.63 [98.3% CI: 22.29; 119.57]) (**Table 2A**). The magnitude of D614G
193 PsVN titers at D15 following monovalent D614 booster in 18–55 year olds were similar in the mRNA
194 and adenoviral vectored priming groups but higher in the group primed with the CoV2 preS dTM-
195 AS03 (D614) vaccine (**Figure 1A**; **Table S2**). Seroreponse rates to D614G ranged from 71.2% to
196 93.1% across priming vaccine subgroups following monovalent D614 booster and was 99.0% (on
197 D36) in the control group among 18–55 year olds (**Table S2**).

198 A similar pattern in D614G PsVN titers was observed in older adults (≥ 56 years) (**Figure S3**). While
199 post-booster GMTs in older adults tended to be of a lower magnitude than those in younger adults,
200 they were still numerically higher than D36 GMTs post-primary vaccination in the control group, for
201 all vaccine-primed subgroups (**Table S2**).

202 *Monovalent B.1.351 booster*

203 In BNT162b2-primed participants aged 18–55 years, B.1.351 PsVN GMTs increased from 200 at D1 to
204 7172 (95% CI 6363; 8083) at D15 following a booster dose of monovalent B.1.351 (**Figure 1B**)

205 demonstrating superiority to pre-booster titers (D15/D1 titer ratio 35.41 [98.3% CI 26.71; 46.95])
206 (**Table 2B**). Comparing B.1.351 PsVN titers following the booster to those following primary
207 vaccination demonstrated non-inferiority to D614G PsVN antibody GMTs (GMT ratio, 1.96 [98.3% CI
208 1.54; 2.50]) and superiority to B.1.351 (GMTR, 17.36 [98.3% CI 13.39; 22.50]) (**Table 2B**).

209 Among participants aged 18–55 years, B.1.351 PsVN GMTs (95% CI) following monovalent B.1.351
210 booster increased from between 49.7 (32.7; 75.6) and 306 (114; 822) at D1 to between 5643 (4468;
211 7128) and 9146 (6734; 12421) at D15 across the mRNA and adenovirus-vectored priming vaccine
212 subgroups (**Figure 1B**). D15 GMTs were 1.5- to 2.5-fold higher than D614G PsVN GMTs following
213 primary vaccination in the control group. PsVN titers (95% CI) against D614G also increased in the
214 monovalent B.1.351 booster group (18–55 years age category) across the four mRNA or adenovirus-
215 vectored priming vaccine subgroups from between 165 (105; 258) and 1331 (917; 1931) at D1 to
216 between 6817 (5453; 8521) and 13189 (9836; 17684) at D15. Seroresponse rates to B.1.351 ranged
217 from 71.4% to 96.5% and those to D614G, from 63.6%–89.1% across priming vaccine subgroups
218 (**Table S4**).

219 PsVN GMTs against B.1.351 and D614G following monovalent B.1.351 booster also increased among
220 older adults (≥ 56 years), with D15 GMTs in all vaccine priming subgroups exceeding those following
221 primary vaccination in the control group (**Figure S3; Table S4**). D15 GMTs in older adults tended to
222 be lower than those in younger participants in all but the mRNA-1273-primed group. Notably, the
223 increase in post-booster PsVN titers following monovalent B.1.351 booster was particularly marked
224 for CoV2 preS dTM-AS03 (D614)-primed participants (≥ 56 years; N=68), with PsVN GMTs (95% CI)
225 rising to 24407 (17705; 33647) (anti-D614G) and 13180 (9571; 18151) (anti-B.1.351). This marked
226 increase in titers was also seen in the 18–55 years age category for a small number (n=4) of
227 participants (**Table S4**).

228 *Bivalent (D614+B.1.351) booster*

229 Among BNT162b2-primed participants aged 18–55 years, PsVN GMTs (95% CI) to D614G increased
230 from 585 (477; 718) at D1 to 8550 (7638; 9571) at D15 and PsVN GMTs to B.1.351 increased from
231 151 (119; 191) at D1 to 5087 (4511; 5737) at D15 following a bivalent booster dose, demonstrating
232 superiority of D614G and B.1.351 booster responses at D15 compared to pre-booster (D15/D1
233 GMTRs [98.3% CI]: 14.39 [11.34; 18.28] and 34.18 [25.84; 45.22], respectively) (**Figure 1C-D; Table**
234 **2C**). The non-inferiority of PsVN titers against D614G and B.1.351 following bivalent booster
235 compared to post-primary D614G PsVN titers in the control group was also demonstrated, with GMT
236 ratios (98.3% CI) of 2.34 (1.84; 2.96) and 1.39 (1.09; 1.77), respectively. In addition, B.1.351 PsVN
237 titers induced by the bivalent booster were demonstrated to be superior to B.1.351 PsVN titers in
238 the control group (GMT ratio, 12.31 [98.3% CI: 9.50; 15.97]) (**Table 2C**).

239 Among 18–55 year olds, D614G and B.1.351 PsVN GMTs following the bivalent booster increased
240 substantially across all vaccine priming subgroups, with GMTRs (post-/pre-booster) ranging from 9 to
241 53 for anti-D614G and from 21 to 107 for anti-B.1.351 (**Figure 1C-D**). Seroresponse rates to D614G
242 ranged from 61.9% (48.8; 73.9) to 89.1% (77.8; 95.9) and those to B.1.351 ranged from 78.3 (95% CI:
243 56.3; 92.5) to 96.4% (95% CI: 87.7; 99.6) across subgroups (**Table S5**).

244 Increases in neutralizing antibody titers (against B.1.351 and against D614G) following the bivalent
245 D614+B.1.351 booster were also seen among older adults (≥56 years) (D15 GMTs: 2025–10035
246 [B.1.351]; 4492–22531 [D614G] across subgroups), with similar or lower PsVN titers compared to
247 younger adults in all but the Ad26.CoV2.S-primed subgroup, in which GMTs were higher in older
248 than younger adults (**Table S5**).

249 *Neutralizing antibody responses to Omicron subvariant strains (exploratory analysis)*

250 In a subset of participants aged 18–55 years (N=132 in the monovalent D614 booster; N=160 in the
251 monovalent B.1.351 group; N=156 in the bivalent booster group), baseline BA.2 PsVN titers were
252 higher in the monovalent B.1.351 and bivalent groups than in the monovalent D614 group. Omicron

253 BA.2 PsVN GMTs increased 19 to 25-fold from baseline following booster, across the three booster
254 groups (**Figure 2A**) with the highest titers induced by the monovalent B.1.351 booster (2663 [95% CI:
255 2260; 3137]), followed by the bivalent booster (1810 [95% CI: 1577; 2077]) and monovalent D614
256 booster (953 [95% CI: 797; 1141]). In older adults (≥ 56 years) (N=74 in the monovalent D614
257 booster; N=59 in the monovalent B.1.351 group; N=33 in the bivalent booster group), while baseline
258 titers were comparable across booster groups, higher titers were elicited by the monovalent B.1.351
259 than by the other formulations. Similar results were obtained for booster responses against the
260 Omicron BA.1 subvariant in BNT162b2-primed participants (**Figure 2B**).

261 **Safety**

262 In each booster group, $\geq 98.0\%$ of participants had completed at least 2 months of safety follow-up
263 by the analysis cut-off dates; the median duration of safety follow-up was 144–150 days across
264 booster groups. In the control group, 70.9% had completed ≥ 2 months safety follow-up and the
265 median duration was 148 days.

266 Adverse events for each booster formulation are summarized in **Table S6**. There were no immediate
267 unsolicited AEs reported in any booster group. Within 7 days after booster, grade 3 solicited
268 injection reactions were reported by 2.5% participants in the monovalent D614 booster group, 3.3%
269 in the monovalent B.1.351 group and 1.9% in the bivalent group (**Figure 3**); grade 3 solicited
270 systemic reactions were reported by 6.6%, 6.9% and 6.3%, respectively (**Figure 4**). Most solicited
271 reactions were transient (mostly lasting 1–3 days) and self-limited; all participants fully recovered.
272 Within 21 days after booster, 7.1–8.8% participants reported at least one unsolicited adverse
273 reaction. Across priming vaccine subgroups, solicited systemic reactions tended to be more
274 frequently reported for CoV2 preS dTM-AS03 (D614)-primed participants than for those primed with
275 other priming vaccines (**Figure S4**). Solicited and unsolicited events were mostly reactogenicity-type
276 events and generally more common in the 18–55 years than the ≥ 56 years group in both booster
277 cohorts (**Supplementary Table S6**).

278 One of 28 SAEs reported up to the analysis cut-off date was assessed as related to the study vaccine
279 (serum sickness-like reaction in a participant primed with mRNA-1273 and boosted with bivalent
280 D614+B.1.351), which resolved 11 days after onset following treatment (antihistamines and steroid
281 cream). One participant aged ≥ 56 years, primed with CoV2 preS dTM-AS03 (D614) and boosted with
282 monovalent B.1.351, reported an AESI (trigeminal neuralgia), assessed as unrelated to vaccination.
283 Of 356 MAAEs reported by 264 booster recipients, eight (2 in the monovalent D614 group, 5 in the
284 monovalent B.1.351 group and 1 in the bivalent D614+B.1.351 group) were assessed as related to
285 the study vaccine. All MAAEs resolved. No deaths and no AEs leading to study discontinuation were
286 reported. No cases of unintentional exposure during pregnancy were reported in any booster group.
287 The safety profile of the control group is summarized in **Supplementary Table S7**. Two participants
288 reported grade 3 immediate unsolicited AEs. One had grade 3 rash, assessed as related and non-
289 serious and resolved on the same day. Another had a grade 3 possible anaphylactic reaction
290 immediately after the second dose (also reported as an AESI and a MAAE), which was assessed as
291 related and resolved with treatment (intramuscular adrenaline and oral prednisone) on the same
292 day. This case did not meet the Brighton Collaboration case definition for anaphylaxis.²³ Solicited
293 reactions were mostly mild to moderate and transient (**Figure 3**). Greater frequency and severity of
294 solicited systemic reactions were reported post-dose 2 compared to post-dose 1, with grade 3
295 solicited systemic reactions reported for 56/456 (12.3%) participants post-dose 1 and 76/377
296 (20.2%) post-dose 2 (**Figure 4**). Unsolicited AEs were mostly of mild or moderate intensity and
297 resolved within 7 days of onset. Eight participants reported eight SAEs in the control group, none
298 assessed as related. One SAE (suicidal ideation) led to study discontinuation. A second AESI (grade 1
299 rheumatoid arthritis) was reported 73 days post-second dose, assessed as not related. Of 121
300 MAAEs reported by 84 participants over the analysis period, 15 (in 8 participants), were assessed as
301 related; all resolved. No deaths were reported. One spontaneous abortion was reported in the
302 control group, assessed as not related to the vaccine. No other exposure during pregnancy was
303 reported in the control group.

304 **Discussion**

305 The findings from this study show that CoV2 preS dTM-AS03 booster vaccines (monovalent D614,
306 monovalent B.1.351 and bivalent D614+B.1.351) are well tolerated and elicit robust neutralizing
307 antibody responses against variants including Omicron in younger and older adults regardless of the
308 vaccine platform used for primary vaccination. Notably, greater neutralizing antibody responses
309 against Omicron BA.2 were achieved after boosting with monovalent B.1.351 than the other
310 formulations.

311 The cross-neutralization of Omicron subvariants following a Beta-variant containing vaccine
312 observed in this study is consistent with initial findings from a phase 3 randomized trial, in which a
313 booster dose of monovalent B.1.351 achieved higher neutralizing antibody titers against Beta, Delta
314 and Omicron BA.1 variants than either a monovalent D614 booster or a third dose of BNT162b2,
315 when administered to adults who previously received a primary vaccination series of BNT162b2.²⁴

316 The cross-neutralization of Omicron subvariants with a Beta-variant containing vaccine has also been
317 observed with the mRNA vaccine platform. A bivalent mRNA COVID-19 vaccine candidate encoding
318 the ancestral SARS-CoV-2 and B.1.351 variant spike protein administered after a primary vaccination
319 series with the original mRNA-1273 elicited robust cross-neutralizing antibodies against Omicron.²⁵

320 This study benefits from a large global study population, inclusive of high-risk groups, thus closely
321 representing the potential target populations. The inclusion of participants previously primed with
322 different vaccine platforms (mRNA, adenovirus-vectored and adjuvant recombinant protein
323 vaccines) including globally deployed vaccines, allowed a comprehensive analysis of prime-boosting
324 options and make our findings applicable to a wide population of individuals. All three CoV2 preS
325 dTM-AS03 booster formulations elicited robust neutralizing antibody responses irrespective of
326 primary vaccination. While higher or similar responses have been previously reported for
327 heterologous prime-boost regimens with mRNA or adenovirus-vectored vaccines compared to
328 homologous prime-boost,²⁶⁻²⁸ the highest responses in the current study were observed following

329 prime-boost with CoV2 preS dTM-AS03 vaccine formulations. These findings may be influenced by
330 the variation in interval between primary and booster injections. Indeed, recent BNT162b2 booster
331 vaccination data suggest that a longer interval (35 weeks or more) may increase vaccine
332 effectiveness,⁶ and previous data have suggested that extended intervals between doses in a
333 primary series of COVID-19 vaccination result in higher neutralizing antibody titers.²⁹ Alternatively,
334 the higher booster responses following CoV2 preS dTM-AS03 priming may result from differences in
335 the priming of the immune system compared to the other priming vaccine platforms, or differences
336 in the proportion of participants who had prior infection.

337 Although rare, higher frequencies than expected of myocarditis and pericarditis have been
338 previously reported following receipt of COVID19 mRNA vaccines³⁰ and with the adjuvanted,
339 protein-based vaccine NVX-CoV2373^{31,32} and an increased risk of thrombosis with
340 thrombocytopenia, following receipt of adenovirus-vectored vaccines.³³ We did not identify any
341 safety concerns in the current study. For all booster groups, reactogenicity tended to be transient,
342 mild to moderate in severity, and similar (for solicited local reactions) or lower (for solicited systemic
343 reactions) post-booster than post-primary vaccination series. The proportion of participants
344 reporting a reactogenicity event after a CoV2 preS dTM-AS03 booster (any grade or grade 3) appears
345 to be similar to or less than that observed after licensed COVID-19 boosters (BNT162b2, mRNA-1273,
346 NVX-CoV2373).³⁴⁻³⁶

347 Some limitations should be noted. Due to a lack of data on previous infection, we cannot make
348 meaningful direct comparisons across booster groups; also, we did not compare data for the ≥56
349 years age category to age-matched controls. The variability in the interval between last primary
350 vaccine dose and booster may have affected the antibody responses to booster vaccination;
351 similarly, the inclusion of immunocompromised participants in our study may have affected the
352 immune responses observed. While our immunogenicity results are promising, it will be important
353 to evaluate the durability of the responses observed in this study, beyond the 15 days post-booster

354 period. Additionally, data on efficacy, as well as on cellular responses elicited by these vaccines, will
355 be needed to understand their potential effectiveness against disease outcomes. Another limitation
356 of our study is the lack of cross-neutralization data on BA.4/5 and more recent variants such as
357 BQ.1.1 and BA.2.75. However, while at the time of writing, the dominant global VoC are Omicron
358 subvariants BA.4 and BA.5,³⁷ the nature of likely future SARS-CoV-2 variants remains unpredictable.
359 Our data indicate that a vaccine containing a B.1.351-component can provide cross-neutralization
360 against a heterologous emergent strain and challenges the current variant-chasing vaccine
361 paradigm.

362 In summary, B.1.351-containing CoV2 preS dTM-AS03 vaccines given as a booster following primary
363 vaccination with globally deployed vaccines elicited strong cross-neutralizing antibody responses
364 against SARS-CoV-2 variants, including against Omicron variants, and had acceptable safety profiles.
365 These findings support the deployment of monovalent B.1.351 as a universal booster against COVID-
366 19.

367 **Author Contributions**

368 GdB, MAC, FTDS, BF, MHG, OH, MK, NLM, RMC, NR, LS, SG, SSa and SSr contributed to the concept
369 or design of the study and data analysis and interpretation; MIB and RM contributed to the
370 conception or design of the study and data acquisition; MSR, HA, SA, DB, AB, RC, SD, DD, AF, RF, JG,
371 PG, DH, OL, JAH, FMT, JP, DMRM, CR, LDS and AW contributed to data acquisition; AP and JW were
372 involved in the analysis and interpretation of the data. All authors were involved in drafting or
373 critically revising the manuscript, and all authors approved the final version and are accountable for
374 the accuracy and integrity of the manuscript. All authors had full access to all the data and accept
375 responsibility to submit for publication.

376 **Declaration of Interests**

377 GdB, JW, AP, MSR, HA, MIB, RC, RF, BF, JG, M-HG, SG, OH, RM, JP, NR, RMC and SSa are Sanofi
378 employees; MIB, RMC hold stock options. SSa was a Sanofi employee at the time of study conduct.
379 SSr, RMC, GdB, CAD and SSa, are inventors on a pending patent application filed by Sanofi and GSK
380 for the development of the CoV-2 dTM vaccine. MAC, LS and MK are employed by GSK and hold
381 restricted shares in the GSK group of companies. FTDS was employed by GSK, and held restricted
382 shares in the GSK group of companies, at the time of the study. DMRM declares that her institution
383 received funding from Sanofi. FM-T has received honoraria from GSK group of companies, Pfizer Inc,
384 Sanofi, MSD, Seqirus, Biofabri, and Janssen for taking part in advisory boards and expert meetings
385 and for acting as a speaker in congresses outside the scope of the submitted work. FM-T has also
386 acted as principal investigator in randomized controlled trials of the above-mentioned companies as
387 well as Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid
388 to his institution. AF receives research funding, paid to his employers, from Sanofi both for work
389 related to this study and other unrelated vaccine trials and from GSK for other unrelated studies. He
390 receives research funding from other vaccine manufacturers relating to trials and studies and

391 undertakes paid consultancy related to a number of developmental antimicrobial drugs and
392 vaccines.

393 **Data sharing statement**

394 Qualified researchers can request access to patient-level data and related study documents,
395 including the clinical study report, study protocol with any amendments, blank case report forms,
396 statistical analysis plan, and dataset specifications. Patient-level data will be anonymised and study
397 documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's
398 data sharing criteria, eligible studies, and process for requesting access can be found at
399 <https://vivli.org/>.

400 **Acknowledgements**

401 The authors thank all participants, investigators, and study site personnel who took part in this
402 study. The authors acknowledge Juliette Gray of inScience Communications, Springer Healthcare,
403 London, UK, for providing editorial assistance with the preparation of this manuscript, funded by
404 Sanofi. The authors also thank Hanson Geevarghese for providing manuscript coordination on behalf
405 of Sanofi. This work was done in collaboration with GSK, who provided access to, and use of, the
406 AS03 Adjuvant System.

407 **Role of the funding source**

408 Funding was provided by Sanofi and by federal funds from the Biomedical Advanced Research and
409 Development Authority, part of the office of the Administration for Strategic Preparedness and
410 Response at the U.S. Department of Health and Human Services under Contract #
411 HHSO100201600005I, and in collaboration with the U.S. Department of Defense Joint Program
412 Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract #
413 W15QKN-16-9-1002. The funders were involved in the study design, data collection, data analysis,

414 data interpretation, writing of the report, and the decision to submit the paper for publication. GSK

415 provided access to, and use of, the AS03 Adjuvant System.

416

References

1. Ssentongo P, Ssentongo AE, Voleti N, et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. *BMC infectious diseases* 2022;22:439.
2. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. *MMWR Morbidity and mortality weekly report* 2022;71:139-45.
3. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nature Medicine* 2022;28:1063-71.
4. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at <https://covid19.who.int/>. Accessed 29 March 2022.
5. World Health Organization. Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines. Available at <https://www.who.int/news/item/17-06-2022-interim-statement-on-decision-making-considerations-for-the-use-of-variant-updated-covid-19-vaccines>. Accessed 27 September 2022. 2022.
6. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. *Nature Medicine* 2022.
7. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. *N Engl J Med* 2022;386:1712-20.
8. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION

Network, 10 States, August 2021-January 2022. MMWR Morbidity and mortality weekly report 2022;71:255-63.

9. Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. *The Lancet Infectious Diseases* 2022;22:1002-10.

10. European Medicines Agency. First adapted COVID-19 booster vaccines recommended for approval in the EU. Available at <https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu>. Accessed 14 September 2022.

11. U.S. Food & Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. Available at <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use>. Accessed 14 September 2022.

12. UK Medicines and Healthcare products Regulatory Agency. Press release: First bivalent COVID-19 booster vaccine approved by UK medicines regulator. Available at <https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator>. Accessed 14 September 2022.

13. UK Medicines and Healthcare products Regulatory Agency. Press release: Pfizer/BioNTech bivalent COVID-19 booster approved by UK medicines regulator. Available at <https://www.gov.uk/government/news/pfizerbiontech-bivalent-covid-19-booster-approved-by-uk-medicines-regulator>. Accessed on 14 September 2022.

14. Sridhar S, Chicz RM, Warren W, et al. The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022. *Nature Communications* 2022;13:5794.

15. Goepfert PA, Fu B, Chabanon AL, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. *Lancet Infect Dis* 2021:1257-70.

16. Sridhar S, Joaquin A, Bonaparte MI, et al. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. *Lancet Infect Dis* 2022.
17. Corbett KS, Gagne M, Wagner DA, et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. *Science* 2021;374:1343-53.
18. Pavot V, Berry C, Kishko M, et al. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. *Nat Commun* 2022;13:1699.
19. Centers for disease control and prevention. Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers. Available at <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>. Accessed on 30 April 2021. 2021.
20. Petropoulos CJ, Parkin NT, Limoli KL, et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. *Antimicrobial Agents and Chemotherapy* 2000;44:920-8.
21. Tavares Da Silva F, De Keyser F, Lambert P-H, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. *Vaccine* 2013;31:1870-6.
22. Barbara Law. Safety Platform for Emergency Vaccines. SO2-D2.1.2 Priority list of COVID-19 adverse events of special interest: quarterly update December 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration; December 23, 2020. Available at https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2_D2.1.2_V1.2_COVID-19_AESI-update-23Dec2020-review_final.pdf. Last accessed November 29, 2022.2020.
23. Law B. SO2- D2.5.2.1 – AESI Case Definition Companion Guide for 1st Tier AESI. Available at https://brightoncollaboration.us/wp-content/uploads/2021/03/SPEAC_D2.5.2.1_Anaphylaxis-Case-Definition-Companion-Guide_V1.0-12070-1.pdf. Accessed 31 May 2022.2021.

24. Launay O, Cachanado M, Luong Nguyen LB, et al. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. *New England Journal of Medicine* 2022;387:374-6.
25. Chalkias S, Eder F, Essink B, et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine. *Nature Medicine* 2022;28:2388–97.
26. Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. *New England Journal of Medicine* 2022;386:1046-57.
27. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet* 2021;398:2258-76.
28. Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans. *New England Journal of Medicine* 2022.
29. Martinez DR, Ooi EE. A potential silver lining of delaying the second dose. *Nature Immunology* 2022;23:349-51.
30. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. *MMWR Morbidity and mortality weekly report* 2021;70:977-82.
31. Department of Health and Aged Care AG. Nuvaxovid (Novavax). Available at <https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/novavax>. Accessed 16 November 2022.
32. Twentyman E, Wallace M, Roper LE, et al. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥ 18 years - United States, July 2022. *MMWR Morbidity and mortality weekly report* 2022;71:988-92.

33. Li X, Burn E, Duarte-Salles T, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. *BMJ* 2022;379:e071594.
34. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nature medicine* 2021;27:2025-31.
35. Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. *Lancet Infect Dis* 2022.
36. U.S. Food and Drug Administration. Application for licensure of a booster dose for COMINARTY (COVID-19 vaccine, mRNA). BNT162b2: evaluation of a booster dose (third dose). Sept 17, 2021. <https://www.fda.gov/media/152176/download>. Accessed October 25, 2022.
37. Tracking SARS-CoV-2 variants. Available at <https://www.who.int/activities/tracking-SARS-CoV-2-variants>. Updated on 25 May 2022. Accessed 01 June 2022.

Tables and Figures

Table 1: Participant demographic characteristics (SafAS)

	CoV2 preS dTM-AS03 booster formulation			Control group
	Monovalent D614 N=803	Monovalent B.1.351 N=705	Bivalent D614+B.1.351 N=621	(two monovalent D614 primary vaccine does) N=473
Sex, n (%)				
Female	434 (54.0)	367 (52.1)	330 (53.1)	210 (44.4)
Male	369 (46.0)	338 (47.9)	291 (46.9)	263 (55.6)
Age, years				
Mean (SD)	50.4 (15.0)	46.0 (15.8)	43.7 (14.3)	37.5 (11.2)
Median (range)	51.0 (18.0; 88.0)	47.0 (18.0; 93.0)	43.0 (18.0; 80.0)	38.0 (18.0; 66.0)
Age category, n (%)				
18-55 years	502 (62.5)	492 (69.8)	483 (77.8)	459 (97.0)
≥56 years	301 (37.5)	213 (30.2)	138 (22.2)	14 (3.0)
Country, n (%)				
Australia	0	39 (5.5)	32 (5.2)	288 (60.9)
France	144 (17.9)	113 (16.0)	116 (18.7)	0
Honduras	43 (5.4)	37 (5.2)	0	0
Spain	0	44 (6.2)	38 (6.1)	0
UK	94 (11.7)	101 (14.3)	110 (17.7)	0
US	522 (65.0)	371 (52.6)	325 (52.3)	185 (39.1)
Race, n (%)				
American Indian or Alaska Native	28 (3.5)	29 (4.1)	10 (1.6)	15 (3.2)
Asian	39 (4.9)	21 (3.0)	25 (4.0)	18 (3.8)
Black or African American	32 (4.0)	91 (12.9)	104 (16.7)	50 (10.6)
Native Hawaiian or Other Pacific Islander	0	3 (0.4)	1 (0.2)	0
White	632 (78.7)	468 (66.4)	407 (65.5)	370 (78.2)
Multiracial	2 (0.2)	10 (1.4)	8 (1.3)	8 (1.7)
Not reported	43 (5.4)	46 (6.5)	58 (9.3)	3 (0.6)
Unknown	27 (3.4)	37 (5.2)	8 (1.3)	9 (1.9)

Ethnicity, n (%)				
Hispanic or Latino	112 (13.9)	103 (14.6)	71 (11.4)	26 (5.5)
Not Hispanic or Latino	656 (81.7)	487 (69.1)	457 (73.6)	390 (82.5)
Not reported	34 (4.2)	102 (14.5)	85 (13.7)	50 (10.6)
Unknown	1 (0.1)	13 (1.8)	8 (1.3)	7 (1.5)
≥1 High-risk medical condition, n (%)				
Yes	408 (50.8)	415 (58.9)	364 (58.6)	283 (59.8)
No	395 (49.2)	290 (41.1)	257 (41.4)	190 (40.2)
Priming vaccine, n (%)				
BNT162b2	328	378	375	na
mRNA-1273	113	111	108	na
ChAdOx1nCoV-19	127	100	100	na
Ad26.CoV2.S	103	38	38	na
CoV2 preS dTM-AS03 (D614)	132	78	na	na
Median interval (IQR), last priming vaccine dose to booster, months	5.75 (4.73; 7.33)	6.96 (5.68; 8.15)	6.50 (5.52; 7.79)	na

IQR=interquartile range (Q1-Q3); na, not applicable; SafAS = safety analysis set.

Table 2. Non-inferiority and superiority of PsVN titers against D614G and B.1.351 following monovalent and bivalent boosters compared with CoV2 preS dTM-AS03 (D614) primary vaccination or compared with pre-booster PsVN titers - PPAS

A. Monovalent D614 booster group

Priming vaccine or vaccine platform subgroup	Booster D15		Control D36		Post-booster vs control			Post-booster vs pre-booster			
	Strain	M	Strain	M	GMT ratio	98.3% CI	NI*	M	GMTR	98.3% CI	Superiority†
BNT162b2	D614G	202	D614G	302	2.16	1.69; 2.75	Yes	189	23.37	18.58; 29.38	Yes
mRNA vaccine platform	D614G	269	D614G	302	2.09	1.66; 2.64	Yes	255	18.08	14.75; 22.16	Yes
Pooled Ad virus vectored platform	D614G	131	D614G	302	1.89	1.43; 2.49	Yes	108	30.18	20.56; 44.31	Yes
CoV2 preS dTM-AS03 (D614)	D614G	52	D614G	302	7.27	5.34; 9.89	Yes	45	51.63	22.29; 119.57	Yes

B. Monovalent B.1.351 booster group

Priming vaccine or vaccine platform subgroup	Booster D15		Control D36		Post-booster vs control			Post-booster vs pre-booster			
	Strain	M	Strain	M	GMT ratio	98.3% CI	NI*	M	GMTR	98.3% CI	Superiority†
BNT162b2	B.1.351	279	D614G	302	1.96	1.54; 2.50	Yes	256	35.41	26.71; 46.95	Yes
	B.1.351	279	B.1.351	291	17.36	13.39; 22.50	Yes‡	-	-	-	-
mRNA vaccine platform	B.1.351	347	D614G	302	2.06	1.62 ; 2.61	Yes	321	34.19	26.58 ; 43.98	Yes

C. Bivalent D614+B.1.351 booster group

Priming vaccine or vaccine platform subgroup	Booster D15		Control D36		Post-booster vs control			Post-booster vs pre-booster			
	Strain	M	Strain	M	GMT ratio	98.3% CI	NI*	M	GMTR	98.3% CI	Superiority†
BNT162b2	D614G	276	D614G	302	2.34	1.84; 2.96	Yes	269	14.39	11.34; 18.28	Yes
	B.1.351	276	D614G	302	1.39	1.09; 1.77	Yes	248	34.18	25.84; 45.22	Yes
	B.1.351	276	B.1.351	291	12.31	9.50; 15.97	Yes‡	-	-	-	-
mRNA vaccine platform	D614G	343	D614G	302	2.52	2.00 ; 3.16	Yes	332	13.04	10.56 ; 16.11	Yes
	B.1.351	342	D614G	302	1.47	1.16 ; 1.85	Yes	309	31.19	24.33 ; 39.97	Yes

D, study day; M, number of participants with available data for the analysis; NI, non-inferiority


*Non-inferiority of a booster response against D614G or B.1.351 compared to a response against D614G in the control group was concluded if the lower bound of the 98.3% CI for the between-group (booster versus control) GMT ratio was >0.67 .

†Superiority of a booster response compared to a pre-booster response was concluded if the lower limit of the 2-sided 98.3% CI of the fold-rise (post-booster versus pre-booster) was >2 .


‡Superiority, rather than non-inferiority, was demonstrated for this comparison (conditional secondary objective). The superiority of a booster dose response against B.1.351 of monovalent B.1.351 or bivalent D614+B.1.351 in BNT162b2 primed participants aged 18-55 years compared to a response against B.1.351 in the control group was concluded if the lower limit of the 2-sided 98.3% CI of the ratio of GMTs between groups was > 1.5 .

Figure 1. Booster pseudovirus neutralizing antibody responses against D614G or B.1.351 strains for (A) monovalent D614, (B) monovalent B.1.351 and (C and D) bivalent D614+B.1.351 among 18–55 year olds, by prior priming vaccine – PPAS


A. Monovalent D614 booster (D614G PsVN titers)




B. Monovalent B.1.351 (B.1.315 PsVN titers)



C. Bivalent D614+B.1.351 (D614G PsVN titers)



D. Bivalent D614+B.1.351 (B.1.315 PsVN titers)



■ D1 ■ D15

Number of participants in each priming group, 18–55 years


Booster group	Strain	BNT		Mod		ChAd		Ad26		AS03-CoV2	
		D1	D15	D1	D15	D1	D15	D1	D15	D1	D15
MV D614	D614G	189	202	66	67	58	68	50	63	45	52
MV B.1.351	B.1.351	256	279	65	68	57	62	22	21	4	4
	D614G	274	279	68	68	55	62	22	22	4	4
BIV	B.1.351	249	276	62	66	57	57	23	25	-	-
	D614G	270	276	64	67	56	57	24	25	-	-

Graphs are annotated with geometric mean titers (above each bar) and geometric means of individual titer ratios (above grouped bars), calculated based on paired post-vaccination/pre-vaccination results. Error bars denote 95% CIs for the GMTs. *95% confidence not calculated due to small number of participants analyzed (n=4). Table shows number of participants with available data for at each timepoint.


D1, study day 1 (pre-booster); D15, study day 15 (14 days post-booster); BNT, BNT162b2-primed; Mod, mRNA-1273-primed; ChAd, ChAdOx1nCoV-19-primed; Ad26, Ad26.CoV2.S-primed; AS03-CoV2, CoV2 preS dTM-AS03 (D614)-primed

Omicron BA.2 and (B) BA.1, by age category

A. Omicron BA.2



B. Omicron BA.1



■ D1 ■ D15

Omicron subvariant	Age group	Number of participants					
		MV D614		MV B.1.351		BiV	
		D1	D15	D1	D15	D1	D15
BA.2*	18-55 yr	110	130	135	159	132	155
	≥56 yr	65	70	53	59	30	33
BA.1†	18-55 yr	18	18	20	20	20	19
	≥56 yr	20	17	10	11	17	17


MV, monovalent; BiV, bivalent

Graphs are annotated with geometric mean titers (above each bar) and geometric means of individual titer ratios (above grouped bars), calculated based on paired post-vaccination/pre-vaccination results. Error bars denote 95% CIs for the GMTs, calculated using normal approximation of log-transformed titers. Table shows number of participants with available data for at each timepoint. *Assessed on available samples across priming vaccine subgroups; †Assessed on available samples in the BNT162b2-primed subgroup


Figure 3. Solicited injection site reactions up to 7 days following vaccination in CoV2 preS dTM-AS03 booster groups and the control group, by age category - SafAS

A. Booster groups


18–55 years age group



≥56 years age group



B. Control group




The percentages of participants experiencing at least one of the specified reactions are shown. Error bars denote 95% CIs for the percentages after any injection, calculated using the Clopper-Pearson method.


MV, monovalent; BiV, bivalent

Figure 4. Solicited systemic reactions up to 7 days following vaccination in CoV2 preS DTM-AS03 booster groups and the control group, by age category – SafAS

A. Booster groups



B. Control group



The percentages of participants experiencing at least one of the specified reactions are shown. Error bars denote 95% CIs for the percentages after any injection, calculated using the Clopper-Pearson method.

MV, monovalent; BiV, bivalent